Immunovant, Inc.
Immunovant, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | -0 | 0 | |||||
Series A Preferred Stock | - | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Excluding Series A Preferred Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 798 | 902 | 995 | 522 | 599 | 714 | 375 | 473 | 560 | 635 | 691 | 270 | |||||
Accounts Receivable Net Current | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 1 | 1 | |||||
Prepaid Expense Current | 53 | 43 | 47 | 50 | 51 | 51 | 36 | 33 | 27 | 25 | 19 | 20 | |||||
Income Taxes Receivable | - | 3 | - | - | - | 0 | - | - | - | 0 | - | - | |||||
Assets Current | 851 | 949 | 1,043 | 574 | 652 | 768 | 413 | 507 | 589 | 666 | 711 | 291 | |||||
Operating Lease Right Of Use Asset | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Property Plant And Equipment Net | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |||||
Other Assets Noncurrent | 1 | 8 | 9 | 9 | 9 | 8 | 8 | 8 | - | 0 | - | - | |||||
Assets | 852 | 957 | 1,052 | 583 | 661 | 776 | 421 | 516 | 590 | 666 | 711 | 292 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 10 | 8 | 9 | 7 | 8 | 18 | 20 | 21 | 11 | 7 | 4 | 8 | |||||
Accrued Liabilities Current | - | 97 | - | - | - | 51 | 48 | 46 | 34 | 41 | 28 | 32 | |||||
Operating Lease Liability Current | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Other Liabilities Current | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | |||||
Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Liabilities Current | 117 | 104 | 66 | 63 | 53 | 69 | 68 | 67 | 45 | 49 | 32 | 40 | |||||
Liabilities | 117 | 104 | 66 | 63 | 53 | 69 | 68 | 67 | 45 | 49 | 32 | 40 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 2,633 | 2,597 | 2,582 | 2,005 | 1,967 | 1,945 | 1,483 | 1,469 | 1,456 | 1,442 | 1,430 | 950 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | -1 | 1 | |||||
Retained Earnings Accumulated Deficit | -1,898 | -1,745 | -1,597 | -1,487 | -1,360 | -1,240 | -1,133 | -1,022 | -913 | -826 | -750 | -699 | |||||
Stockholders Equity | 735 | 853 | 986 | 520 | 609 | 707 | 353 | 449 | 545 | 618 | 679 | 252 | |||||
Liabilities And Stockholders Equity | 852 | 957 | 1,052 | 583 | 661 | 776 | 421 | 516 | 590 | 666 | 711 | 292 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | - | - | - | |||||
Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | |||||
Common Stock Shares Issued | 206 | 204 | 203 | 175 | 171 | 170 | 147 | 147 | 146 | 146 | 145 | 131 | |||||
Shares Outstanding | 206 | 204 | 203 | 175 | 171 | 170 | 147 | 147 | 146 | 146 | 145 | 131 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027 | - | - | - | - | - | - | - | - | - | - | - | - |
| 2026 | 16.12% | 14.50% | 67.21% | -2.27% | 10.87% | 11.25% | 2.51% | -11.35% | 5.66% | -5.46% | 11.67% | - |
| 2025 | 10.95% | 0.61% | 8.51% | -5.78% | -18.18% | -22.99% | 1.18% | -9.77% | -27.70% | 6.11% | 20.28% | 2.22% |
| 2024 | 7.48% | 72.00% | 49.73% | 29.51% | 34.56% | 22.17% | -13.63% | -14.20% | -21.34% | -7.61% | -5.41% | 1.62% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 | 7.23 | |||||
| Quick Ratio | 6.82 | 8.68 | 15.03 | 8.28 | 11.36 | 10.42 | 5.52 | 7.12 | 12.49 | 13.18 | 21.56 | 6.74 | |||||
| Working Capital | 734.08M | 844.40M | 976.68M | 510.29M | 598.86M | 698.89M | 344.23M | 440.72M | 544.03M | 617.16M | 678.67M | 250.92M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.16 | 0.12 | 0.07 | 0.12 | 0.09 | 0.10 | 0.19 | 0.15 | 0.08 | 0.08 | 0.05 | 0.16 | |||||
| Interest Coverage TTM | -19.66 | -18.95 | -18.06 | -18.75 | -17.65 | -15.70 | -13.57 | -9.56 | -8.69 | -9.37 | -11.17 | -17.17 | |||||
| Debt Ratio | 0.14 | 0.11 | 0.06 | 0.11 | 0.08 | 0.09 | 0.16 | 0.13 | 0.08 | 0.07 | 0.05 | 0.14 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Receivables Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -2.62 | -2.77 | -2.56 | -2.68 | -2.62 | -2.73 | -2.60 | -2.21 | -1.87 | -1.88 | -1.68 | -1.95 | |||||
| Free Cash Flow Per Share TTM | -2.59 | -1.67 | -1.77 | -1.89 | -1.16 | -2.48 | -2.22 | -1.86 | -1.67 | -1.55 | -1.46 | -1.60 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | 20.32% | 22.17% | 21.29% | 43.86% | 64.12% | 59.58% | 57.20% | 26.54% | 11.46% | 22.93% | 22.52% | 44.33% | |||||
| EPS Growth (1Y) | 0.03% | 1.51% | -1.82% | 21.35% | 40.31% | 45.39% | 54.64% | 13.31% | -0.43% | 9.56% | 9.00% | 28.28% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -14.71 | -8.96 | -9.94 | -6.02 | -6.11 | -6.26 | -9.51 | -12.93 | -14.15 | -17.21 | -25.01 | -19.73 | |||||
| P/B TTM | 10.77 | 5.31 | 4.68 | 5.39 | 4.49 | 3.66 | 10.32 | 9.30 | 7.08 | 7.22 | 8.96 | 20.00 | |||||
| Market Cap | 7.92B | 4.53B | 4.61B | 2.80B | 2.73B | 2.59B | 3.64B | 4.18B | 3.86B | 4.46B | 6.09B | 5.04B | |||||
| Enterprise Value | 7.12B | 3.63B | 3.62B | 2.28B | 2.14B | 1.88B | 3.26B | 3.70B | 3.30B | 3.83B | 5.40B | 4.77B | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -531.72M | -304.80M | -320.57M | -328.82M | -197.74M | -376.63M | -325.64M | -272.30M | -243.55M | -214.59M | -210.56M | -209.82M | |||||
| Net Debt | -797.80M | -902.11M | -994.53M | -521.87M | -598.91M | -713.97M | -374.69M | -472.94M | -560.01M | -635.37M | -690.94M | -269.93M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Immunovant, Inc. (IMVT) — SEC Financial Statements & Analysis
Immunovant, Inc. (IMVT) is a biological products, (no diagnostic substances) company, incorporated in DE. Immunovant, Inc. trades on Nasdaq as: IMVT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Immunovant, Inc. reported a Debt-to-Equity ratio of 0.16x, a Price-to-Book (P/B) ratio of 10.77x (TTM), at a market cap of $7.92B. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.16x
- P/B TTM
- 10.77x
- Market Cap
- $7.92B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Immunovant, Inc. in?
Immunovant, Inc. (IMVT) operates in the Biological Products, (No Diagnostic Substances) industry.
What is IMVT's market cap?
Immunovant, Inc. (IMVT) has a market capitalization of $7.92B as of 2026-06-30.
What exchange does IMVT trade on?
Immunovant, Inc. (IMVT) trades on the Nasdaq.
Where is Immunovant, Inc. incorporated?
Immunovant, Inc. is incorporated in DE.